Making cancer treatments affordable today won’t hurt tomorrow’s innovation

12 May 2021 - Congress is about to debate legislation—the Lower Drug Costs Now Act (H.R.3)—that would give Medicare the ...

Read more →

ICER publishes evidence report on therapies for multiple myeloma

5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...

Read more →

ICER releases draft evidence report on therapies for multiple myeloma

11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting ...

Read more →

ICER publishes final evidence report and policy recommendations on new therapies for bladder cancer

17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...

Read more →

ICER publishes evidence report on new therapies for bladder cancer

6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...

Read more →

ICER to assess CAR-T cell therapies for multiple myeloma

31 August 2020 - Report will be subject of Midwest CEPAC meeting in April 2021; open input now being accepted until ...

Read more →

The global imperative to make cancer medications affordable

1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...

Read more →

Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

14 October 2019 - Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But ...

Read more →

ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer

24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...

Read more →

Institute for Clinical and Economic Review report finds inadequate evidence to compare PARP inhibitors across key ovarian cancer indications

30 August 2017 - The ICER has released an evidence report assessing the comparative clinical effectiveness and value of three ...

Read more →

Institute for Clinical and Economic Review posts draft scoping document on CAR-T therapies for public comment

9 August 2017 - Report expected to review axicabtagene ciloleucel and tisagenlecleucel-t, first CAR-T therapies submitted for FDA. ...

Read more →

ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer

12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...

Read more →

Converging on the value of value frameworks

6 June 2017 - The relentless increase in health care costs has been difficult to control and is widely believed to ...

Read more →

ICER releases evidence report on treatments for non-small cell lung cancer

29 September 2016 - The Institute for Clinical and Economic Review has released an evidence report assessing the comparative clinical effectiveness ...

Read more →

What they are saying about ICER's scoping document for non-small cell lung cancer

11 July 2016 - The ICER has set its sights on a new target: life-saving treatments for advanced non-small cell lung ...

Read more →